Patients in the U.K. with transfusion-dependent beta-thalassemia will have access to Vertex Pharmaceuticals’s gene editing therapy Casgevy, thanks to an agreement with the NHS England on the price. hubs.li/Q02KyZ2G0 #pharma #biospace